



**BioLight Life Sciences Ltd.**  
**(the “Company”)**

October 18 2023

**Re: DiagnosTear Ltd. (Subsidiary) –**  
**recruitment of last participant in a clinical trial in India**

BioLight hereby announces that its subsidiary, Diagnostear Ltd. ("Diagnostear") has informed it that the last participant (out of 600 participants) has been recruited for the clinical trial being conducted in India to evaluate the product developed by Diagnostear, based on the TeaRx™ technology (the “Product”) for diagnosing Dry Eye Syndrome ("DES") by examining the composition of tear fluid (the “Trial”).

This announcement is in continuation of the Company's reports from October 19, 2021, regarding the recruitment of the first participant in the Trial, and from December 26, 2022, concerning positive interim results in the Trial.

According to Diagnostear's estimate, as provided to the Company, the monitoring period for the dry eye patients who participated in the Trial and attended review meetings is expected to conclude in the first quarter of 2024, and the final results are expected to be received thereafter.

***Forward Looking Statement*** *The information and details contained in this report regarding the clinical trial as well as predictions, deadlines, assessments and/or plans of the Company and/or Diagnostear in connection with the aforementioned, including in connection with the achievement of the goals of the trial (if any) as well as further examination and development, are "Forward-looking information" as defined in the Israeli Securities Law, 1968-5778 which involves high uncertainty, and is based, among other things, on third parties and on many variables over which the Company and/or Diagnostear do not necessarily have*

*control, and therefore it is possible that the aforementioned information and estimates, in practice will not be realized and/or will not be fully realized and/or will be realized in a materially different way than was initially estimated or observed, including as a result of any of the risk factors as detailed in Section 4.27 in Chapter A of the Company's annual report, which may have a significant effect, together and separately, on the Company's estimates as mentioned above.*

### **About DiagnosTear**

DiagnosTear develops the TeaRx™ Technology designed for the identification, diagnosis, adjustment of treatment, and follow-up of diseases in the front of the eye by examining the composition of the tear fluid

### **About BioLight**

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects in the field of eye diseases and ocular treatments. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine designed to improve the efficacy and safety of treatments of eye diseases exemplifying the enormous potential of Israeli innovation in these fields.

### **Free translation: non-binding.**

*This is a translated version of the Company's immediate report in Hebrew as filed with the Tel Aviv Stock Exchange – created for convenience purposes only. In case of contradiction, the Hebrew version will take precedence.*